Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Liphekolo Tse Hlahisitsoeng Ha Pele Kalafo ea Kankere ea Matsoele e Fana ka Tšepo

ngotsoeng ke mohlophisi

Lefats'eng ka bophara, R&D mabapi le mofetše oa matsoele ka mefuta eohle ea eona e ntse e hola butle butle ka lebelo le leholo lilemong tse 'maloa tse fetileng mme e tla tsoela pele lilemong tse tlang. Kankere ea matsoele ke mofetše oa bobeli o atileng lefatšeng ka bophara ebile ke mofetše o atileng ho fetisisa ho basali lefatšeng ka bophara.

Mofetše oa matsoele oa epidermal growth factor receptor 2-positive (HER2+) o etsa hoo e ka bang 20% ​​ea linyeoe tsa mofetše oa matsoele 'me nalane e ne e amahanngoa le bofokoli bo bobe ha ho se na liphekolo tse sebetsang. Ho elelloa hore ho hlahisa liphekolo tse lebisitsoeng ho HER2 pejana leanong la taolo ea mafu ho ka ntlafatsa ho phela ntle le maloetse (DFS) ho thehile mmaraka o moholo oa liphekolo tse tsamaisitsoeng ke HER2. Kajeno, bakuli ba mofetše oa matsoele ba HER2+ ba phela nako e telele le lefu la bona, ka lebaka la maano a theohileng a taolo ea mafu a sebelisa mekhoa. Ho latela Stats Market Research, mmaraka oa HER2+ o lebeletsoe esale pele hore o tla hola ho fihla ho $12.1B ka 2030, ka Sekhahla sa Kholiso ea Selemo le Selemo sa Motsoako (CAGR) sa 1.5%. Tlaleho e tsoang ho Mordor Intelligence e ekelitse hore 'maraka oa kalafo ea mofetše oa matsoele o lebelletsoe ho hola ho CAGR ea 8.3% nakong ea kemiso, 2022-2027. 

Tlaleho e itse: "Ka lebaka la ho phatloha ha COVID-19, 'maraka o tobane le tšitiso e nyane ka lebaka la tieho ea tlhahlobo, khaello ea lithethefatsi, le ho se fumanehe ha litsebi tsa bophelo bo botle. Mohlala, ho latela sengoloa se phatlalalitsoeng ho JAMA Network ka Phato 2020, ho bile le phokotseho e kholo ea tlhahlobo ea mofetše oa matsoele (ka hoo e ka bang 51.8%) United States ho tloha ka la 1 Hlakubele 2020 ho fihlela la 18 Mmesa 2020. , ho lieha ho hlahlojoa ha kankere ea matsoele ho amme phekolo e tšoanang. Kahoo, seoa sa COVID-19 se amme hampe 'maraka oa kalafo ea mofetše oa matsoele karolong ea ona ea pele. Leha ho le joalo, 'maraka o lebelletsoe ho hola lilemong tse tlang ha kalafo e ntse e tsoela pele lefatšeng ka bophara. ” Likhamphani tse sebetsang tsa biotech le pharma 'marakeng bekeng ena li kenyelletsa Oncolytics Biotech® Inc., Clovis Oncology, Inc., Belite Bio Inc., Endo International plc, Pfizer Inc.

Patlisiso ea Maraka ea Stats e tsoetse pele: "Ho feta moo, lintlha tse ka sehloohong tse hlohlelletsang kholo ea 'maraka ke sekhahla se phahameng sa sekhahla le sekhahla sa ho ata ha mofetše oa matsoele lefats'eng ka bophara, ho eketsa matsete lipatlisisong le nts'etsopele, le tsoelo-pele ea baeloji ea mofets'e le pharmacology e khothaletsang nts'etsopele ea lithethefatsi. Palo e phahameng ea sekhahla le sekhahla sa ho ata ha mofetše oa matsoele lefatšeng ka bophara ke eona ntho e ka sehloohong e tsamaisang kholo ea 'maraka. Ka Amerika Leboea, United States e lebelletsoe ho laola 'maraka ka kakaretso nakong eohle ea kemiso. Lintlha tse ka sehloohong tse matlafatsang kholo ea 'maraka ke moroalo o ntseng o eketseha oa mofetše oa matsoele naheng le tlhokomeliso e ntseng e eketseha e mabapi le mofetše oa matsoele hammoho le ho hlahisoa ha lihlahisoa tse ntseng li eketseha. ”

Oncolytics Biotech® le SOLTI li Hlahisa Lintlha tse Ncha tsa Clinical Biomarker tse Bontšang Monyetla oa Pelareorep oa ho Ntlafatsa Phatlalatso ea Bakuli ba Kankere ea Matsoele Sebokeng sa Kankere ea Matsoele ea ESMO - Oncolytics Biotech® le SOLTI-Innovative Cancer Research kajeno e phatlalalitse lintlha tse ncha tsa bongaka tsa biomarker tse bonts'ang litlamorao tsa immunotherapeutic Thibelo ea ho hlahloba, le monyetla oa ho ntlafatsa pono ea bakuli ba nang le mofetše oa matsoele oa HR+/HER2-. Lintlha, tse hlahisitsoeng tlhahisong ea poster ho 2022 European Society for Medical Oncology (ESMO) Seboka sa Kankere ea Matsoele, li tsoa ho sehlopha sa 1 le sa 2 sa thuto ea monyetla ea AWARE-1 ​​ho bakuli ba mofetše oa matsoele ba mothating oa pele.

Bakuli ba lihlopha tse peli tsa pele tsa AWARE-1 ​​ba ile ba phekoloa ka pelareorep le aromatase inhibitor letrozole ntle le (cohort 1), kapa ka (cohort 2), PD-L1 checkpoint inhibitor atezolizumab hoo e ka bang matsatsi a 21 pele ho ts'ebetso ea ho buuoa ea lihlahala tsa bona. Cohorts 1 le 2 ea AWARE-1 ​​bakuli ba ngolisitseng ka ho khetheha ba nang le lefu la HR+/HER2-, subtype ea kankere ea matsoele eo Oncolytics e ikemiselitseng ho e hlahloba thutong e tlang ea ngoliso. Liphetho tse tlalehiloeng pele li bonts'itse AWARE-1 ​​e fihletse pheletso ea eona ea mantlha ea phetolelo, 'me sehlopha sa 2 se fihletse litekanyetso tse boletsoeng esale pele tsa katleho bakeng sa keketseho e bakiloeng ke kalafo ho lintlha tsa CelTIL (link ho PR). Lintlha tsa CelTIL ke metric bakeng sa ho ruruha ha tumor le cellularity mme e amahanngoa le liphetho tse ntlafalitsoeng tsa bongaka ho bakuli ba mofetše oa matsoele.

"Lintlha tsa morao-rao tse tsoang ho AWARE-1 ​​li bonts'a hape bokhoni ba pelareorep ba ho ntlafatsa sephetho sa bongaka ho bakuli ba mofetše oa matsoele ka bokhoni ba bona ba ho kenya lisele tsa T ts'ebetsong le ho nchafatsa tikoloho ea tumor," ho boletse Thomas Heineman, MD, Ph.D., Ofisiri e ka Sehloohong ea Bongaka ea Oncolytics. . "Habohlokoa, kalafo ea pelareorep e ekelitse matšoao a lefu la lisele tsa hlahala 'me, mohlomong le ho feta, 100% ea bakuli ba ka hlahlojoang ba tšoaroang ke pelareorep ba ne ba e-na le Risk of Recurrence Score (ROR-S) e ntle ha e bapisoa le 55% qalong. Ka kopanelo, liphetho tsena tsa morao-rao tsa AWARE-1 ​​li tiisa bokhoni ba pelareorep ba ho hlasela lihlahala ka mekhoa e mengata. ”

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...